Crossmark

Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective

Published Online: 2025-05-16

Published Print: 2025-07

Authors

Buchler, Tomas https://orcid.org/0000-0001-6667-994X
Funding

Funding for this research was provided by:

Charles University
License Information

Text and Data Mining valid from 2025-05-16

Version of Record valid from 2025-05-16
More Information

Article History

Accepted: 24 April 2025

First Online: 16 May 2025

Declarations

:

: Open access publishing supported by the institutions participating in the CzechELib Transformative Agreement.

: Tomas Buchler: Research support from AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi/Aventis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol-Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All unrelated to the present paper. Tomas Buchler is an Editorial Board member of Targeted Oncology. Tomas Buchler was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Review design, first draft, editing: Buchler.

Document is current